Tsutsumi Y, Shimono J, Ohhigashi H, Ito S, Shiratori S, Teshima T
Department of Hematology, Hakodate Municipal Hospital, Hakodate, Japan.
Int J Lab Hematol. 2015 Apr;37(2):225-30. doi: 10.1111/ijlh.12270. Epub 2014 Jun 25.
Dabigatran is an oral intake thrombin inhibitor for preventive administration against stroke accompanied by atrial fibrillation. Although dabigatran causes prolonged activated partial thromboplastin time (APTT), the effect of dabigatran on each coagulation factor and coagulation factor inhibitor remains to be investigated. Our aim was to analyze the influence of dabigatran on coagulation factors and coagulation factor inhibitors.
We administered dabigatran to 40 patients. In 26 of these 40, we analyzed the activity of several coagulation factors and their inhibitors. We used Fisher's exact test to determine statistical significance.
The activities of many coagulation factors changed during the dabigatran therapy. Factor II levels decreased in all patients showing prolongation of partial thromboplastin (PT) and APTT. The antifactor VIII inhibitor was positive in the majority of patients with prolonged PT and APTT, while activities of protein C, protein S, and antifactor IX inhibitor were not associated with PT and APTT prolongation.
Dabigatran affects the activities of many coagulation factors, including factors II, V, VIII, and IX, as well as the antifactor VIII inhibitor.
达比加群是一种口服凝血酶抑制剂,用于预防伴有房颤的中风。尽管达比加群会导致活化部分凝血活酶时间(APTT)延长,但达比加群对各凝血因子及凝血因子抑制剂的影响仍有待研究。我们的目的是分析达比加群对凝血因子及凝血因子抑制剂的影响。
我们对40例患者给予达比加群。在这40例患者中的26例,我们分析了几种凝血因子及其抑制剂的活性。我们使用Fisher精确检验来确定统计学意义。
在达比加群治疗期间,许多凝血因子的活性发生了变化。所有部分凝血活酶时间(PT)和APTT延长的患者,其凝血因子II水平均下降。大多数PT和APTT延长的患者,其抗凝血因子VIII抑制剂呈阳性,而蛋白C、蛋白S及抗凝血因子IX抑制剂的活性与PT和APTT延长无关。
达比加群会影响许多凝血因子的活性,包括凝血因子II、V、VIII和IX,以及抗凝血因子VIII抑制剂。